Sanofi Pasteur SA - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Sanofi Pasteur SA - Product Pipeline Review - 2016', provides an overview of the Sanofi Pasteur SA's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sanofi Pasteur SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sanofi Pasteur SA - The report provides overview of Sanofi Pasteur SA including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sanofi Pasteur SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sanofi Pasteur SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Sanofi Pasteur SA's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sanofi Pasteur SA - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sanofi Pasteur SA's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Sanofi Pasteur SA Snapshot 6 Sanofi Pasteur SA Overview 6 Key Information 6 Key Facts 6 Sanofi Pasteur SA - Research and Development Overview 7 Key Therapeutic Areas 7 Sanofi Pasteur SA - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Sanofi Pasteur SA - Pipeline Products Glance 15 Sanofi Pasteur SA - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Filing rejected/Withdrawn Products/Combination Treatment Modalities 16 Phase III Products/Combination Treatment Modalities 17 Sanofi Pasteur SA - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Sanofi Pasteur SA - Early Stage Pipeline Products 20 Discovery Products/Combination Treatment Modalities 20 Sanofi Pasteur SA - Drug Profiles 21 dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 influenza [serotypes A, B] (split virion, tetravalent) vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 (diphtheria + tetanus + pertussis (acellular)) vaccine 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Clostridium difficile vaccine 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ETEC vaccine 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 influenza [strain A/H7N9] vaccine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 rabies [strain Wistar PM/WI 38-1503-3M] vaccine 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 tuberculosis vaccine 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 VCP-2438 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 HSV-529 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pneumococcal (trivalent) vaccine 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Streptococcus pneumonia vaccine 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 VCP-2292 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 infectious disease vaccine 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 influenza vaccine 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Sanofi Pasteur SA - Pipeline Analysis 45 Sanofi Pasteur SA - Pipeline Products by Target 45 Sanofi Pasteur SA - Pipeline Products by Route of Administration 46 Sanofi Pasteur SA - Pipeline Products by Molecule Type 47 Sanofi Pasteur SA - Recent Pipeline Updates 48 Sanofi Pasteur SA - Dormant Projects 54 Sanofi Pasteur SA - Discontinued Pipeline Products 55 Discontinued Pipeline Product Profiles 55 meningitis [serotype B] vaccine 55 Sanofi Pasteur SA - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Sanofi Pasteur SA, Key Information 6 Sanofi Pasteur SA, Key Facts 6 Sanofi Pasteur SA - Pipeline by Indication, 2016 8 Sanofi Pasteur SA - Pipeline by Stage of Development, 2016 10 Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016 11 Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016 12 Sanofi Pasteur SA - Partnered Products in Pipeline, 2016 13 Sanofi Pasteur SA - Partnered Products/ Combination Treatment Modalities, 2016 14 Sanofi Pasteur SA - Pre-Registration, 2016 15 Sanofi Pasteur SA - Filing rejected/Withdrawn, 2016 16 Sanofi Pasteur SA - Phase III, 2016 17 Sanofi Pasteur SA - Phase II, 2016 18 Sanofi Pasteur SA - Phase I, 2016 19 Sanofi Pasteur SA - Discovery, 2016 20 Sanofi Pasteur SA - Pipeline by Target, 2016 45 Sanofi Pasteur SA - Pipeline by Route of Administration, 2016 46 Sanofi Pasteur SA - Pipeline by Molecule Type, 2016 47 Sanofi Pasteur SA - Recent Pipeline Updates, 2016 48 Sanofi Pasteur SA - Dormant Developmental Projects,2016 54 Sanofi Pasteur SA - Discontinued Pipeline Products, 2016 55 Sanofi Pasteur SA, Other Locations 56 Sanofi Pasteur SA, Subsidiaries 57
List of Figures
Sanofi Pasteur SA - Pipeline by Top 10 Indication, 2016 8 Sanofi Pasteur SA - Pipeline by Stage of Development, 2016 10 Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016 11 Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016 12 Sanofi Pasteur SA - Partnered Products in Pipeline, 2016 13 Sanofi Pasteur SA - Pipeline by Target, 2016 45 Sanofi Pasteur SA - Pipeline by Route of Administration, 2016 46 Sanofi Pasteur SA - Pipeline by Molecule Type, 2016 47
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.